CWEB

Why Do You Have To Be Careful With TransEnterix Stock TransEnterix, ( TRXC ) Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. According to recent studies Robotic assisted minimally invasive surgery does not appear to offer any clinical benefits over conventional laparoscopic techniques in terms of outcomes and complication rates but is associated with significantly higher costs, two new studies of cancers indicate. TransEnterix surgical bot, Senhance, only does laparoscopic surgery. The Senhance is an old surgical robot, approved in Europe in 2011, and only three have been sold by TransEnterix in Europe. This report will likely have negative implications for TransEnterix financial top and bottom lines. <iframe width="560" height="315" src="https://www.youtube.com/embed/9TXBP1t2rUc" frameborder="0" allow="autoplay; encrypt...

Why Is AYTU A Strong Buy And Potential Buy Out By Leslie CohenManaging Editor Aytu BioScience, Inc.AYTU  ( OTC:AYTU )  is a small-cap stock operating in the pharmaceutical industry dedicated to improving Urological health for men worldwide. The Company addresses problems like insomnia, male infertility, and hypogonadism. Their portfolio of products included Natesto , Zolpimist, and MiOXSYS® Aytu BioScience  ( OTC:AYTU )  Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist(NYSE: TM ) to Expand Company's Commercial-Stage Product Portfolio Natesto is the first FDA-approved intranasal testosterone replacement therapy. ZOLPIMIST™ (zolpidem tartrate) Oral Spray, the only FDA-approved oral spray zolpidem product indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation and is available both in the US and internationally. Zolpidem tartrate has been shown to decrease the time i...

Netflix: Loyal Subscribers Love Netflix- And So Does Wall Street By: Leslie Cohen Great news for Netflix, Inc. ( NFLX ) as it will replace Monsanto in the S&P 100. Monsanto is being acquired by BAYER (BAY.TI). Netflix’s stock closed up 1.1% to $365.80 on Tuesday, June 5 th  2018. The way we view entertainment has changed. Kannan Venkateshwar, media analyst of Barclays Capital states, “ We believe the economics for companies with global streaming scale like Netflix may be more favorable than theatrical releases, over time.” Netflix has given control over to the consumer on how they watch movies. And- consumer are loving it. It gives the viewer a wide choice of content that is viewable any time- on demand, and on any device. What’s not to love about Netflix? “13 Reasons Why” one of Netflix’s most popular shows drawing an audience in the second season of an average audience of 2.6 million viewers in the U.S. , all within the first three days on air, according...

CWEB.com - Why Neovasc Inc Is A Very Dangerous Stock  Neovasc Inc (NASDAQ, TSX: NVCN) a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Legal actions are still not settled and may impede future cash flows. Projections of net income losses bring into question liquidity problems. Industry competitiveness and consolidation will bring on a new set of challenges. "Remaining on the Nasdaq Capital Market ("Nasdaq") is a critical piece of the Company's turnaround strategy," commented Fred Colen , Neovasc's President and Chief Executive Officer. "Without reaching a minimum bid...

Groupon Still The King of Daily Deals - CWEB.com By: Leslie Cohen Managing Editor Strong growth in and platform initiatives raises full year 2018 adjusted ebitda outlook gross profit of $324.9 million net loss from continuing operations of $2.8 million adjusted ebitda of $52.6 million gaap loss per diluted share of $0.01. 61.90% of Groupon Shares are owned by institutional investors. Strong institutional ownership indicates big money managers and hedge funds believe that a company is poised for long-term growth.  The number of shares currently selling short amount to 8.6% of shares outstanding with an uptick of 3.23% last month. Groupon is down 6.08 this year, but Wall Street is bullish on the stock. The analysts that cover Groupon have a buy equivalent rating on it.  Analysts are suggesting a 17-point percentage game recent close. Vanguard Group Inc., which owns 34,432,805 shares of the stock are valued at $159.77 million.   The third l...

Can CVS Health Buy BioPharmX Corporation? - CWEB.com Corporate health-care deal value surged 37 percent last year, according to a new report from consulting firm Bain & Company. The number of health-care mergers and acquisitions rose 16 percent. CVS Health's planned acquisition of health insurer Aetna was the largest corporate deal of 2017 at $69 billion. The health-care shopping spree isn't likely to stop anytime soon. Corporate deal value surged to $332 billion last year, up 27 percent from $261 billion in 2016, though still below the peak of $432 billion in 2015, according to a  new report  from consulting firm Bain & Company. What does make BioPharmX unique? Financial Health : Does it have a healthy balance sheet? Management :Have insiders been ramping up their shares to take advantage of the market’s sentiment for BPMX’s future outlook? Other High-Growth Alternatives : BPMX is a high-growth stock you could be holding? Walgreens  was also...

Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com Institutional investors currently hold major shares in BioPharmX Corporation( BPMX ) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018 BioPharmX Corporation ( BPMX ) stock was most active stock of Wall Street Market on Tuesday. BPMX moved -1.77% to 0.19. BPMX received interesting focus from Active Investors and it has been trading on front line as seeing to it recent volume. Statistic show the size of the acne treatment market worldwide in 2016 and a forecast for 2025, in billion U.S. dollars. In 2016, the global acne treatment market was worth some 4.9 billion dollars and was expected to grow to over 7 billion by the end of 2025. Statistic also show the market value of skincare products in Great Britain from 2009 to 2016. The total value of the skincare market in December 2016 was measured at approximately 2.16 bill...